Insider Selling: Nautilus Biotechnology (NASDAQ:NAUT) Major Shareholder Sells 5,000,000 Shares of Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of Nautilus Biotechnology stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the sale, the insider owned 971,885 shares of the company’s stock, valued at approximately $2,283,929.75. The trade was a 83.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Nautilus Biotechnology Stock Performance

Nautilus Biotechnology stock traded up $0.10 during mid-day trading on Thursday, hitting $2.68. 300,368 shares of the company traded hands, compared to its average volume of 311,885. The stock has a market cap of $340.57 million, a price-to-earnings ratio of -5.83 and a beta of 0.75. Nautilus Biotechnology, Inc. has a one year low of $0.62 and a one year high of $4.31. The stock has a fifty day moving average price of $2.92 and a 200-day moving average price of $2.45.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Tuesday, April 28th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02.

Wall Street Analyst Weigh In

NAUT has been the subject of a number of recent research reports. Guggenheim boosted their price objective on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.00.

Hedge Funds Weigh In On Nautilus Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC grew its stake in shares of Nautilus Biotechnology by 5.4% in the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock worth $1,989,000 after purchasing an additional 52,448 shares during the last quarter. Sentinel Trust Co. LBA purchased a new position in Nautilus Biotechnology during the 4th quarter valued at about $1,462,000. Geode Capital Management LLC raised its position in Nautilus Biotechnology by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock valued at $1,094,000 after purchasing an additional 7,307 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in Nautilus Biotechnology by 860.0% in the 2nd quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock worth $316,000 after buying an additional 390,000 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Nautilus Biotechnology by 15.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 329,123 shares of the company’s stock worth $1,274,000 after buying an additional 43,684 shares during the period. 50.71% of the stock is owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.